Interim data from Aptevo Therapeutics Inc.'s ongoing RAINIER clinical trial indicates that the company's investigational therapy mipletamig, when combined with standard frontline treatment for acute myeloid leukemia (AML), delivers an 86% clinical benefit rate with a favorable safety profile. The combination of mipletamig with venetoclax and azacitidine achieved a 79% remission rate among evaluable newly diagnosed AML patients, with 55% of those achieving remission reaching MRD-negative status where highly sensitive tests could not detect remaining leukemia cells.
The emerging data suggest mipletamig may enhance current frontline AML treatment approaches while maintaining the safety and tolerability needed for older patients or those with other health conditions who cannot tolerate intensive chemotherapy. Notably, no patients treated to date have experienced cytokine release syndrome (CRS), a common and potentially serious immune reaction that can force patients to discontinue therapy. This safety profile is particularly important for drugs intended to be used in combination with other treatments, where tolerability is key to keeping patients on therapy.
Mipletamig is a bispecific antibody designed to target CD123, a marker commonly found on AML leukemia cells, while simultaneously connecting with T-cells to direct the immune system to attack and destroy cancer cells. This targeted approach aims to activate immune response against AML while maintaining a safety profile that allows combination with existing frontline treatments. The RAINIER trial, a phase 1b dose optimization study, is evaluating mipletamig in combination with venetoclax and azacitidine in newly diagnosed AML patients who are older or unable to receive intensive chemotherapy.
AML affects approximately 22,000 people in the United States annually and remains one of the most aggressive adult leukemias. For patients who cannot tolerate intensive treatment, therapeutic advances that improve outcomes without adding significant toxicity represent an important medical need. The company's phase 1b trial is designed to determine the optimal dose, followed by a larger phase 2 study to further evaluate effectiveness. More information about the company and its development programs can be found at https://www.aptevotherapeutics.com.
According to Marvin White, President and Chief Executive Officer of Aptevo Therapeutics, the frontline data show mipletamig has the potential to play a meaningful role in future frontline AML treatment. The combination of strong remission outcomes with continued absence of cytokine release syndrome represents an encouraging efficacy and safety profile for therapies intended to work in combination with existing frontline AML treatments. The original research findings were published through https://www.newmediawire.com.
